Jean-simon Diallo

Biography

Dr. Jean-Simon Diallo obtained his bachelor’s degree in biochemistry with honours in bioinformatics from the University of Ottawa in 2000. He went on to Montreal to pursue a masters’ degree in biochemistry at McGill University where he studied the epigenetic regulation of globin genes with the late Dr. Lee Wall. In 2003, he began his Ph.D in molecular biology at the Université de Montréal, in the laboratory of Drs. Anne-Marie Mes-Masson and Fred Saad. There he studied prognostic markers/models for prostate cancer as well as the use of naturally occurring phytochemicals for prostate cancer therapy. Funded by the Fonds de Recherche en Santé du Quebec (FRSQ) fellowship, he joined Dr. John Bell’s lab as a postdoctoral fellow in 2007, applying his broad expertise and collaborative approach to the field of oncolytic viruses. In Dr. Bell’s group, Dr. Diallo pioneered high-throughput methods to identify compounds that enhance viral replication. Now an Associate Scientist at the OHRI working with a multidisciplinary network of collaborators, he and his team are using medicinal chemistry, mass spectrometry and high-throughput molecular biology approaches to study how “viral sensitizer” drugs work. He is also expanding the scope of application of viral sensitizer drugs, which in addition to oncolytic virotherapy, show tremendous promise in virus/vaccine manufacturing and gene therapy applications.   Dr. Jean-Simon Diallo obtained his bachelor’s degree in biochemistry with honours in bioinformatics from the University of Ottawa in 2000. He went on to Montreal to pursue a masters’ degree in biochemistry at McGill University where he studied the epigenetic regulation of globin genes with the late Dr. Lee Wall. In 2003, he began his Ph.D in molecular biology at the Université de Montréal, in the laboratory of Drs. Anne-Marie Mes-Masson and Fred Saad. There he studied prognostic markers/models for prostate cancer as well as the use of naturally occurring phytochemicals for prostate cancer therapy. Funded by the Fonds de Recherche en Santé du Quebec (FRSQ) fellowship, he joined Dr. John Bell’s lab as a postdoctoral fellow in 2007, applying his broad expertise and collaborative approach to the field of oncolytic viruses. In Dr. Bell’s group, Dr. Diallo pioneered high-throughput methods to identify compounds that enhance viral replication. Now an Associate Scientist at the OHRI working with a multidisciplinary network of collaborators, he and his team are using medicinal chemistry, mass spectrometry and high-throughput molecular biology approaches to study how “viral sensitizer” drugs work. He is also expanding the scope of application of viral sensitizer drugs, which in addition to oncolytic virotherapy, show tremendous promise in virus/vaccine manufacturing and gene therapy applications.  

Research Interest

Oncolytic virotherapy Virus-based therapeutics Innate antiviral response High-throughput screening/biology Viral sensitizer drugs Biotherapeutics manufacturing Biochemistry